The changing landscape in the treatment of metastatic castration-resistant prostate cancer

Therapeutic Advances in Medical Oncology

Volumn 5, Issue 1, 2013, Pages 25-40

  Amm, Joelle ^a   Aragon Ching, Jeanny B ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Androgen deprivation therapy; chemotherapy; metastatic castration resistant prostate cancer; vaccine therapy

Indexed keywords

ABIRATERONE ACETATE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ARN 509; CABAZITAXEL; CABOZANTINIB; CUSTIRSEN; DENOSUMAB; DOCETAXEL; ENZALUTAMIDE; GALETERONE; IPILIMUMAB; LENALIDOMIDE; MITOXANTRONE; OGX 427; ORTERONEL; PLACEBO; PREDNISONE; RADIUM CHLORIDE RA 223; RILIMOGENE GALVACIREPVEC; SIPULEUCEL T; TASQUINIMOD; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; BACKACHE; BONE DISEASE; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLUID RETENTION; HEART DISEASE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; IMMUNOTHERAPY; INFUSION RELATED REACTION; JAW OSTEONECROSIS; KIDNEY FAILURE; MAXIMUM TOLERATED DOSE; METASTASIS; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKELETAL RELATED EVENT; STEROIDOGENESIS; THROMBOCYTOPENIA; TREMOR;

EID: 84877625347     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012458137     Document Type: Review

References (67)

1. Aragon-Ching J. (2011) Unravelling the role of denosumab in prostate cancer. Lancet 377: 785–786.
2. Aragon-Ching J. Dahut W. (2007) Chemotherapy in androgen-independent prostate cancer (AIPC): what's next after taxane progression? Cancer Ther 5A: 151–160.
3. Aragon-Ching J. Ning Y. Chen C. Latham L. Guadagnini J. Gulley J. et al. (2009) Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 27: 221–226.
4. Armstrong A. Garrett-Mayer E. Yang Y. de Wit R. Tannock I. Eisenberger M. (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX 327 study analysis. Clin Cancer Res 13: 6396–6403.
5. Armstrong A. George D. (2010) Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. Prostate Cancer Prostatic Dis 13: 108–116.
6. Attard G. Belldegrun A. de Bono J. (2005) Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96: 1241–1246.
7. Beltran H. Beer T. Carducci M. de Bono J. Gleave M. Hussain M. et al. (2011) New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol 60: 279–290.
8. Cai C. Portnoy D. Wang H. Jiang X. Chen S. Balk S. (2009) Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res 69: 5202–5209.
9. Chambers J. Neumann P. (2011) Listening to Provenge – what a costly cancer treatment says about future Medicare policy. N Engl J Med 364: 1687–1689.
10. Chi K. Gleave M. Klasa R. Murray N. Bryce C. Lopes de Menezes D. et al. (2001) A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 7: 3920–3927.
11. Chi K. Hotte S. Ellard S. Gingerich J. Joshua A. Yu E. et al. (2012) A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC). J Clin Oncol 30(Suppl.): abstract 4514.
12. Chi K. Hotte S. Yu E. Tu D. Eigl B. Tannock I. et al. (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28: 4247–4254.
13. Clegg N. Wongvipat J. Joseph J. Tran C. Ouk S. Dilhas A. et al. (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 72: 1494–1503.
14. Crawford E. Flaig T. (2012) Optimizing outcomes of advanced prostate cancer: drug sequencing and novel therapeutic approaches. Oncology (Williston Park) 26: 70–77.
15. Danila D. Heller G. Gignac G. Gonzalez-Espinoza R. Anand A. Tanaka E. et al. (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13: 7053–7058.
16. de Bono J. Logothetis C. Molina A. Fizazi K. North S. Chu L. et al. (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364: 1995–2005.
17. de Bono J. Oudard S. Ozguroglu M. Hansen S. Machiels J. Kocak I. et al. (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376: 1147–1154.
18. de Bono J. Scher H. Montgomery R. Parker C. Miller M. Tissing H. et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14: 6302–6309.
19. Eisenberger M. Simon R. O'Dwyer P. Wittes R. Friedman M. (1985) A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3: 827–841.
20. Fizazi K. Carducci M. Smith M. Damiao R. Brown J. Karsh L. et al. (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377: 813–822.
21. Fong L. Kwek S. O'Brien S. Kavanagh B. McNeel D. Weinberg V. et al. (2009) Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA 4 blockade and GM-CSF. Cancer Res 69: 609–615.
22. Gulley J. Arlen P. Madan R. Tsang K. Pazdur M. Skarupa L. et al. (2010) Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 59: 663–674.
23. Halabi S. Small E. Kantoff P. Kattan M. Kaplan E. Dawson N. et al. (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21: 1232–1237.
24. Halabi S. Vogelzang N. Kornblith A. Ou S. Kantoff P. Dawson N. et al. (2008) Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26: 2544–2549.
25. Hamberg P. Verhagen P. de Wit R. (2008) When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer? Eur J Cancer 44: 1193–1197.
26. Handratta V. Vasaitis T. Njar V. Gediya L. Kataria R. Chopra P. et al. (2005) Novel C-17-heteroaryl steroidal CYP 17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC 4 human prostate cancer xenograft model. J Med Chem 48: 2972–2984.
27. Higano C. Schellhammer P. Small E. Burch P. Nemunaitis J. Yuh L. et al. (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115: 3670–3679.
28. Higano C. Small E. Schellhammer P. Yasothan U. Gubernick S. Kirkpatrick P. et al. (2010) Sipuleucel-T. Nat Rev Drug Discov 9: 513–514.
29. Huber M. Haynes L. Parker C. Iversen P. (2012) Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst 104: 273–279.
30. Hussain M. Smith M. Sweeney C. Corn P. Elfiky A. Gordon M. et al. (2011) Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol 29(Suppl.): abstract 4516.
31. Kaku T. Hitaka T. Ojida A. Matsunaga N. Adachi M. Tanaka T. et al. (2011) Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 19: 6383–6399.
32. Kantoff P. Higano C. Shore N. Berger E. Small E. Penson D. et al. (2010 a) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411–422.
33. Kantoff P. Schuetz T. Blumenstein B. Glode L. Bilhartz D. Wyand M. et al. (2010 b) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28: 1099–1105.
34. Kelly W. Halabi S. Carducci M. George D. Mahoney J. Stadler W. et al. (2012) Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30: 1534–40.
35. Liepe K. (2009) Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. Curr Opin Investig Drugs 10: 1346–1358.
36. Lin A. Ryan C. Small E. (2007) Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol 61: 243–254.
37. Madan R. Aragon-Ching J. Gulley J. Dahut W. (2011) From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines 10: 743–753.
38. Madan R. Gulley J. Fojo T. Dahut W. (2010) Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 15: 969–975.
39. Mathew P. Dipaola R. (2007) Taxane refractory prostate cancer. J Urol 178: S36–S41.
40. Miyake H. Nelson C. Rennie P. Gleave M. (2000) Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer. Cancer Res 60: 170–176.
41. Mostaghel E. Marck B. Plymate S. Vessella R. Balk S. Matsumoto A. et al. (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17: 5913–5925.
42. Ning Y. Gulley J. Arlen P. Woo S. Steinberg S. Wright J. et al. (2010) Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28: 2070–2076.
43. Odero-Marah V. Wang R. Chu G. Zayzafoon M. Xu J. Shi C. et al. (2008) Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res 18: 858–870.
44. Pal S. Twardowski P. Sartor O. (2010) Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging 5: 395–402.
45. Peppercorn J. Armstrong A. Zaas D. George D. (2012) Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer. Urol Oncol 3 February (epub ahead of print).
46. Petrylak D. Tangen C. Hussain M. Lara P. Jr Jones J.M. et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513–1520.
47. Pili R. Haggman M. Stadler W. Gingrich J. Assikis V. Bjork A. et al. (2011) Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J Clin Oncol 29: 4022–4028.
48. Rocchi P. So A. Kojima S. Signaevsky M. Beraldi E. Fazli L. et al. (2004) Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 64: 6595–6602.
49. Roodman G. (2004) Mechanisms of bone metastasis. N Engl J Med 350: 1655–1664.
50. Ryan C. Li J. Kheoh T. Scher H. Molina A. (2012 a) Baseline serum adrenal androgens are prognostic and predictive of overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): results of the COU-AA-301 phase 3 randomized trial. Cancer Res 72 (8 Suppl.): LB-434.
51. Ryan C. Smith M. de Bono J. Molina A. Logothetis C. de Souza P. et al. (2012 b) Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 30 (Suppl.): abstract LBA4518.
52. Ryan C. Smith M. Fong L. Rosenberg J. Kantoff P. Raynaud F. et al. (2010) Phase I clinical trial of the CYP 17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28: 1481–1488.
53. Saad F. Hotte S. North S. Eigl B. Chi K. Czaykowski P. et al. (2011) Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 17: 5765–5773.
54. Sartor O. Heinrich D. Helle S. O'Sullivan J. Fossa S. Chodacki A. et al. (2012) Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: a phase III randomized trial (ALSYMPCA). J Clin Oncol 30 (Suppl. 5): abstract 9.
55. Sartor O. Reid R. Hoskin P. Quick D. Ell P. Coleman R. et al. (2004) Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63: 940–945.
56. Scher H. Beer T. Higano C. Anand A. Taplin M. Efstathiou E. et al. (2010) Antitumour activity of MDV 3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375: 1437–1446.
57. Scher H. Fizazi K. Saad F. Taplin M. Sternberg C. Miller K. et al. (2012) Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol 30(Suppl. 5): abstract LBA1.
58. Siegel R. Naishadham D. Jemal A. (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10–29.
59. Slovin S. (2012) Chemotherapy and immunotherapy combination in advanced prostate cancer. Clin Adv Hematol Oncol 10: 90–100.
60. Smaletz O. Scher H. Small E. Verbel D. McMillan A. Regan K. et al. (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20: 3972–3982.
61. Small E. Demkow T. Gerritsen W. Rolland F. Hoskin P. Smith D. et al. (2009) A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). J Clin Oncol 27(15 Suppl.): abstract 7.
62. Small E. Schellhammer P. Higano C. Redfern C. Nemunaitis J. Valone F. et al. (2006) Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24: 3089–3094.
63. Smith M. Egerdie B. Hernandez Toriz N. Feldman R. Tammela T. Saad F. et al. (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361: 745–755.
64. Smith M. Saad F. Coleman R. Shore N. Fizazi K. Tombal B. et al. (2012) Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379: 39–46.
65. Tannock I. de Wit R. Berry W. Horti J. Pluzanska A. Chi K. et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (15): 1502–1512.
66. Tannock I. Osoba D. Stockler M. Ernst D. Neville A. Moore M. et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756–1764.
67. Tran C. Ouk S. Clegg N. Chen Y. Watson P. Arora V. et al. (2009) Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324: 787–790.